Entrada Therapeutics, Inc. TRDA
We take great care to ensure that the data presented and summarized in this overview for Entrada Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TRDA
View all-
Baker Bros. Advisors LP New York, NY4.87MShares$63.5 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$57.5 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$57.1 Million60.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$37.9 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$27.1 Million0.02% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$22.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.46MShares$19.1 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA1.03MShares$13.5 Million0.0% of portfolio
-
Step Stone Group LP La Jolla, CA761KShares$9.93 Million26.04% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA585KShares$7.63 Million1.65% of portfolio
Latest Institutional Activity in TRDA
Top Purchases
Top Sells
About TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Transactions at TRDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2024
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
21,787
-0.49%
|
$435,740
$20.23 P/Share
|
|
Dec 11
2024
|
Mpm Bioventures 2018, L.P. |
SELL
Open market or private sale
|
Indirect |
21,787
-0.49%
|
$435,740
$20.23 P/Share
|
|
Dec 10
2024
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
22,935
-0.52%
|
$458,700
$20.77 P/Share
|
|
Dec 10
2024
|
Mpm Bioventures 2018, L.P. |
SELL
Open market or private sale
|
Indirect |
22,935
-0.52%
|
$458,700
$20.77 P/Share
|
|
Dec 03
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
11,703
-7.47%
|
$234,060
$20.15 P/Share
|
|
Dec 02
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
4,088
-2.54%
|
$81,760
$20.26 P/Share
|
|
Dec 02
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.34%
|
$100,000
$20.0 P/Share
|
|
Dec 02
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.96%
|
$10,000
$2.1 P/Share
|
|
Nov 29
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$2,000
$20.0 P/Share
|
|
Nov 29
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.34%
|
$19,000
$19.97 P/Share
|
|
Nov 29
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.32%
|
$2,000
$2.1 P/Share
|
|
Nov 13
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
2,700
-1.65%
|
$54,000
$20.04 P/Share
|
|
Nov 11
2024
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,637
-10.47%
|
$164,103
$19.98 P/Share
|
|
Nov 11
2024
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+6.78%
|
$12,000
$2.1 P/Share
|
|
Nov 11
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
1,409
-0.85%
|
$28,180
$20.01 P/Share
|
|
Nov 06
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
12,299
-3.51%
|
$233,681
$19.01 P/Share
|
|
Nov 05
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
5,171
-2.83%
|
$93,078
$18.18 P/Share
|
|
Nov 04
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
749
-0.41%
|
$13,482
$18.02 P/Share
|
|
Oct 16
2024
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Open market or private sale
|
Direct |
600
-0.33%
|
$10,800
$18.0 P/Share
|
|
Sep 26
2024
|
Nathan J Dowden President & COO |
SELL
Open market or private sale
|
Direct |
847
-0.67%
|
$13,552
$16.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 273K shares |
|---|---|
| Exercise of conversion of derivative security | 52.9K shares |
| Open market or private purchase | 45.4K shares |
| Payment of exercise price or tax liability | 28.3K shares |
|---|---|
| Open market or private sale | 213K shares |